Economic consequences of sequencing biologics in rheumatoid arthritis: A systematic review

Journal of Medical Economics

Volumn 16, Issue 3, 2013, Pages 391-396

  Sullivan, Sean D ^a   Alfonso Cristancho, Rafael ^a   Carlson, Josh ^a   Mallya, Usha ^b   Ringold, Sarah ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Biologics; Cost effectiveness; Rheumatoid arthritis; Sequencing; TNF Inhibitor

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; DRUG SUBSTITUTION; HUMANS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873935565     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.763812     Document Type: Review

References (26)

1. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39
2. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96
3. Devine EB, Cristancho-Alfonso R, Sullivan SD. Effectiveness of biologic therapies in rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011;31:39-51
4. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275
5. Furst DE, Pangan AL, Harrold LR, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res 2011;63:856-64
6. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
7. Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47:507-13
8. van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007;66: 849-51
9. Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42
10. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8
11. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003
12. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-229
13. Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-278
14. Launois R, Payet S, Saidenberg-Kermanac'h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008;75:688-95
15. Walsh CA, Minnock P, Slattery C, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 2007;46:1148-52
16. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008;35:1745-53
17. Davies J, Cifaldi MA, Segurado OG, et al. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009;36:16-26
18. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009;25:181-9
19. Russell A, Beresniak A, Bessette L, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009;28:403-12
20. Hallinen TA, Soini EJ, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology 2010;49:767-77
21. Saraux A, Gossec L, Goupille P, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology 2010;49:733-40
22. Merkesdal S, Kirchhoff T, Wolka D, et al. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ 2010;11:95-104
23. Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, et al. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam 2011; 2011:727634. doi: 10.4061/2011/727634. Epub 28 Jun 2011
24. Cimmino MA, Leardini G, Salaffi F, et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol 2011;29:633-41
25. Puolakka K, Blåfield H, Kauppi M, et al. Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open Rheumatol J 2012;6:38-43
26. Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:1-91